Maxim Group restated their buy rating on shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) in a report released on Thursday morning. They currently have a $4.00 price objective on the biopharmaceutical company’s stock.
Shares of ContraVir Pharmaceuticals (NASDAQ:CTRV) opened at 2.34 on Thursday. The stock’s market cap is $125.55 million. The stock’s 50 day moving average is $1.18 and its 200 day moving average is $1.06. ContraVir Pharmaceuticals has a 12 month low of $0.76 and a 12 month high of $2.65.
Several hedge funds and other institutional investors have recently bought and sold shares of CTRV. Prospera Financial Services Inc increased its stake in ContraVir Pharmaceuticals by 0.6% in the second quarter. Prospera Financial Services Inc now owns 178,550 shares of the biopharmaceutical company’s stock worth $186,000 after buying an additional 1,000 shares during the period. Vanguard Group Inc. increased its stake in ContraVir Pharmaceuticals by 8.7% in the second quarter. Vanguard Group Inc. now owns 915,369 shares of the biopharmaceutical company’s stock worth $952,000 after buying an additional 73,135 shares during the period. Finally, Teachers Advisors Inc. increased its stake in ContraVir Pharmaceuticals by 95.2% in the second quarter. Teachers Advisors Inc. now owns 289,919 shares of the biopharmaceutical company’s stock worth $1,102,000 after buying an additional 141,368 shares during the period.
ContraVir Pharmaceuticals Company Profile
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of virology drugs to treat diseases of unmet needs, such as herpes zoster and hepatitis B (HBV). It is developing targeted antiviral therapies with over two drug candidates in clinical studies. Its FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743 that it is developing for the treatment of herpes zoster, which is an infection caused by the reactivation of varicella zoster virus or VZV.
Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.